Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.

Abstract:

Importance:Dietary fiber (the main source of prebiotics) and yogurt (a probiotic food) confer various health benefits via modulating the gut microbiota and metabolic pathways. However, their associations with lung cancer risk have not been well investigated. Objective:To evaluate the individual and joint associations of dietary fiber and yogurt consumption with lung cancer risk and to assess the potential effect modification of the associations by lifestyle and other dietary factors. Design, Setting, and Participants:This pooled analysis included 10 prospective cohorts involving 1 445 850 adults from studies that were conducted in the United States, Europe, and Asia. Data analyses were performed between November 2017 and February 2019. Using harmonized individual participant data, hazard ratios and 95% confidence intervals for lung cancer risk associated with dietary fiber and yogurt intakes were estimated for each cohort by Cox regression and pooled using random-effects meta-analysis. Participants who had a history of cancer at enrollment or developed any cancer, died, or were lost to follow-up within 2 years after enrollment were excluded. Exposures:Dietary fiber intake and yogurt consumption measured by validated instruments. Main Outcomes and Measures:Incident lung cancer, subclassified by histologic type (eg, adenocarcinoma, squamous cell carcinoma, and small cell carcinoma). Results:The analytic sample included 627 988 men, with a mean (SD) age of 57.9 (9.0) years, and 817 862 women, with a mean (SD) age of 54.8 (9.7) years. During a median follow-up of 8.6 years, 18 822 incident lung cancer cases were documented. Both fiber and yogurt intakes were inversely associated with lung cancer risk after adjustment for status and pack-years of smoking and other lung cancer risk factors: hazard ratio, 0.83 (95% CI, 0.76-0.91) for the highest vs lowest quintile of fiber intake; and hazard ratio, 0.81 (95% CI, 0.76-0.87) for high vs no yogurt consumption. The fiber or yogurt associations with lung cancer were significant in never smokers and were consistently observed across sex, race/ethnicity, and tumor histologic type. When considered jointly, high yogurt consumption with the highest quintile of fiber intake showed more than 30% reduced risk of lung cancer than nonyogurt consumption with the lowest quintile of fiber intake (hazard ratio, 0.67 [95% CI, 0.61-0.73] in total study populations; hazard ratio, 0.69 [95% CI, 0.54-0.89] in never smokers), suggesting potential synergism. Conclusions and Relevance:Dietary fiber and yogurt consumption was associated with reduced risk of lung cancer after adjusting for known risk factors and among never smokers. Our findings suggest a potential protective role of prebiotics and probiotics against lung carcinogenesis.

journal_name

JAMA Oncol

journal_title

JAMA oncology

authors

Yang JJ,Yu D,Xiang YB,Blot W,White E,Robien K,Sinha R,Park Y,Takata Y,Lazovich D,Gao YT,Zhang X,Lan Q,Bueno-de-Mesquita B,Johansson I,Tumino R,Riboli E,Tjønneland A,Skeie G,Quirós JR,Johansson M,Smith-Warner SA

doi

10.1001/jamaoncol.2019.4107

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

e194107

issue

2

eissn

2374-2437

issn

2374-2445

pii

2753175

journal_volume

6

pub_type

杂志文章
  • Resource Use and Medicare Costs During Lay Navigation for Geriatric Patients With Cancer.

    abstract:Importance:Lay navigators in the Patient Care Connect Program support patients with cancer from diagnosis through survivorship to end of life. They empower patients to engage in their health care and navigate them through the increasingly complex health care system. Navigation programs can improve access to care, enhan...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.6307

    authors: Rocque GB,Pisu M,Jackson BE,Kvale EA,Demark-Wahnefried W,Martin MY,Meneses K,Li Y,Taylor RA,Acemgil A,Williams CP,Lisovicz N,Fouad M,Kenzik KM,Partridge EE,Patient Care Connect Group.

    更新日期:2017-06-01 00:00:00

  • Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

    abstract:Importance:Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective:To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive of HFS. Design, Setting, and Participants:This single-center, rando...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2017.1269

    authors: Yap YS,Kwok LL,Syn N,Chay WY,Chia JWK,Tham CK,Wong NS,Lo SK,Dent RA,Tan S,Mok ZY,Koh KX,Toh HC,Koo WH,Loh M,Ng RCH,Choo SP,Soong RCT

    更新日期:2017-11-01 00:00:00

  • Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

    abstract:Importance:Aromatase inhibitors (AI) are associated with significant urogenital atrophy, affecting quality of life and drug compliance. Objective:To evaluate safety of intravaginal testosterone cream (IVT) or an estradiol-releasing vaginal ring (7.5 μg/d) in patients with early-stage breast cancer (BC) receiving an AI...

    journal_title:JAMA oncology

    pub_type: 杂志文章,随机对照试验

    doi:10.1001/jamaoncol.2016.3904

    authors: Melisko ME,Goldman ME,Hwang J,De Luca A,Fang S,Esserman LJ,Chien AJ,Park JW,Rugo HS

    更新日期:2017-03-01 00:00:00

  • Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.

    abstract:Importance:The androgen receptor inhibitor enzalutamide prolongs survival in men with metastatic castration-resistant prostate cancer (mCRPC). In controlled clinical studies, 0.5% (10 of 2051) of patients experienced seizure, but patients with a history of or risk factors for seizure were excluded. Men with mCRPC and s...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2017.3361

    authors: Slovin S,Clark W,Carles J,Krivoshik A,Park JW,Wang F,George D

    更新日期:2018-05-01 00:00:00

  • Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

    abstract:Importance:The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.5801

    authors: Abida W,Cheng ML,Armenia J,Middha S,Autio KA,Vargas HA,Rathkopf D,Morris MJ,Danila DC,Slovin SF,Carbone E,Barnett ES,Hullings M,Hechtman JF,Zehir A,Shia J,Jonsson P,Stadler ZK,Srinivasan P,Laudone VP,Reuter V,Wo

    更新日期:2019-04-01 00:00:00

  • Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.

    abstract:Importance:To date, the benefit of genome-driven cancer therapy has not been quantified. Objective:We sought to estimate the annual percentage of patients in the United States with advanced or metastatic cancer who could be eligible for and benefit from US Food and Drug Administration (FDA)-approved genome-driven ther...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1660

    authors: Marquart J,Chen EY,Prasad V

    更新日期:2018-08-01 00:00:00

  • Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

    abstract:Importance:Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. Objective:To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fl...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.3797

    authors: Tejpar S,Stintzing S,Ciardiello F,Tabernero J,Van Cutsem E,Beier F,Esser R,Lenz HJ,Heinemann V

    更新日期:2017-02-01 00:00:00

  • Nonadherence to Medications for Chronic Conditions and Nonadherence to Adjuvant Hormonal Therapy in Women With Breast Cancer.

    abstract:Importance:While adjuvant hormonal therapy (HT) reduces mortality for women with nonmetastatic breast cancer, nonadherence to HT is common. Objective:We investigated the association between patterns of prior nonadherence to medications for chronic conditions with HT nonadherence. Design, Setting, and Participants:For...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2016.1291

    authors: Neugut AI,Zhong X,Wright JD,Accordino M,Yang J,Hershman DL

    更新日期:2016-10-01 00:00:00

  • Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.

    abstract:Importance:Osteosarcoma, the most common malignant bone tumor in children and adolescents, occurs in a high number of cancer predisposition syndromes that are defined by highly penetrant germline mutations. The germline genetic susceptibility to osteosarcoma outside of familial cancer syndromes remains unclear. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.0197

    authors: Mirabello L,Zhu B,Koster R,Karlins E,Dean M,Yeager M,Gianferante M,Spector LG,Morton LM,Karyadi D,Robison LL,Armstrong GT,Bhatia S,Song L,Pankratz N,Pinheiro M,Gastier-Foster JM,Gorlick R,de Toledo SRC,Petrilli AS,

    更新日期:2020-05-01 00:00:00

  • Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A Review.

    abstract:Importance:Multiple myeloma (MM) is the second most common hematological malignant abnormality. The introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has greatly improved the overall survival of patients with MM. Prevention and treatment of cardiovascular and thrombotic issues associated wi...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2016.3350

    authors: Li W,Garcia D,Cornell RF,Gailani D,Laubach J,Maglio ME,Richardson PG,Moslehi J

    更新日期:2017-07-01 00:00:00

  • Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

    abstract:IMPORTANCE:Objective response rate (ORR) is an increasingly important end point for accelerated development of highly active anticancer therapies, yet its relationship to regulatory approval is not well characterized. OBJECTIVE:To identify circumstances in which a high ORR is associated with regulatory approval, and t...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析

    doi:10.1001/jamaoncol.2015.6315

    authors: Oxnard GR,Wilcox KH,Gonen M,Polotsky M,Hirsch BR,Schwartz LH

    更新日期:2016-06-01 00:00:00

  • Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.

    abstract:Importance:The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear. Objective:To assess the association of adjuvant chemotherapy with overall survival (OS) in patients afte...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.3537

    authors: van Roessel S,van Veldhuisen E,Klompmaker S,Janssen QP,Abu Hilal M,Alseidi A,Balduzzi A,Balzano G,Bassi C,Berrevoet F,Bonds M,Busch OR,Butturini G,Del Chiaro M,Conlon KC,Falconi M,Frigerio I,Fusai GK,Gagnière J,Grif

    更新日期:2020-09-10 00:00:00

  • Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

    abstract:Importance:Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age. Objective:To assess the survival impact of SPMs in...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2017.0465

    authors: Keegan THM,Bleyer A,Rosenberg AS,Li Q,Goldfarb M

    更新日期:2017-11-01 00:00:00

  • Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

    abstract:Importance:The role of cytoreductive nephrectomy in patients with metastatic renal cancer in the era of targeted therapy is uncertain. Objective:To establish the safety and efficacy of upfront pazopanib therapy prior to cytoreductive nephrectomy in previously untreated patients with metastatic clear cell renal cancer....

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2016.1197

    authors: Powles T,Sarwar N,Stockdale A,Sarker SJ,Boleti E,Protheroe A,Jones R,Chowdhury S,Peters J,Oades G,O'Brien T,Sullivan M,Aitchison M,Beltran L,Worth D,Smith K,Michel C,Trevisan G,Harvey-Jones E,Wimalasingham A,Sahde

    更新日期:2016-10-01 00:00:00

  • Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.

    abstract:IMPORTANCE:A recent randomized radiation dose-escalation trial in unresectable stage III non-small-cell lung cancer (NSCLC) (Radiation Therapy Oncology Group [RTOG] 0617) showed a lower survival rate in the high-dose radiation therapy (RT) arm (74 Gy) than in the low-dose arm (60 Gy) with concurrent chemotherapy. OBJE...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2015.3969

    authors: Movsas B,Hu C,Sloan J,Bradley J,Komaki R,Masters G,Kavadi V,Narayan S,Michalski J,Johnson DW,Koprowski C,Curran WJ Jr,Garces YI,Gaur R,Wynn RB,Schallenkamp J,Gelblum DY,MacRae RM,Paulus R,Choy H

    更新日期:2016-03-01 00:00:00

  • Use and Effectiveness of Adjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer in Men.

    abstract:Importance:Although adjuvant endocrine therapy confers a survival benefit among females with hormone receptor (HR)-positive breast cancer, the effectiveness of this treatment among males with HR-positive breast cancer has not been rigorously investigated. Objective:To investigate trends, patterns of use, and effective...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.1114

    authors: Venigalla S,Carmona R,Guttmann DM,Jain V,Freedman GM,Clark AS,Shabason JE

    更新日期:2018-10-01 00:00:00

  • The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.

    abstract:IMPORTANCE:Although axillary lymph node evaluation is standard of care in the surgical management of invasive breast cancer, a benefit has not been demonstrated in ductal carcinoma in situ (DCIS). Despite uncertainty regarding the efficacy, axillary evaluation is often performed in women with DCIS. OBJECTIVE:To determ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.0389

    authors: Coromilas EJ,Wright JD,Huang Y,Feldman S,Neugut AI,Chen L,Hershman DL

    更新日期:2015-06-01 00:00:00

  • Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

    abstract:Importance:Pathologic complete response (pCR) is a known prognostic biomarker for long-term outcomes. The I-SPY2 trial evaluated if the strength of this clinical association persists in the context of a phase 2 neoadjuvant platform trial. Objective:To evaluate the association of pCR with event-free survival (EFS) and ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2535

    authors: I-SPY2 Trial Consortium.,Yee D,DeMichele AM,Yau C,Isaacs C,Symmans WF,Albain KS,Chen YY,Krings G,Wei S,Harada S,Datnow B,Fadare O,Klein M,Pambuccian S,Chen B,Adamson K,Sams S,Mhawech-Fauceglia P,Magliocco A,Feldma

    更新日期:2020-09-01 00:00:00

  • Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond.

    abstract:IMPORTANCE:E-cadherin (CDH1) is a cancer predisposition gene mutated in families meeting clinically defined hereditary diffuse gastric cancer (HDGC). Reliable estimates of cancer risk and spectrum in germline mutation carriers are essential for management. For families without CDH1 mutations, genetic-based risk stratif...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2014.168

    authors: Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor N

    更新日期:2015-04-01 00:00:00

  • Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review.

    abstract:Importance:Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-cell therapy, was the first US Food and Drug Administration-approved, genetically engineered T-cell therapy for adults with relapsed or refractory large B-cell lymphoma (LBCL) after 2 or more lines of systemic therapy. There has not ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,评审

    doi:10.1001/jamaoncol.2019.3869

    authors: Locke FL,Go WY,Neelapu SS

    更新日期:2020-02-01 00:00:00

  • Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors.

    abstract:Importance:Approximately 50% of the risk for the development of testicular germ cell tumors (TGCTs) is estimated to be heritable, but no mendelian TGCT predisposition genes have yet been identified. It is hypothesized that inherited pathogenic DNA repair gene (DRG) alterations may drive susceptibility to TGCTs. Object...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.6477

    authors: AlDubayan SH,Pyle LC,Gamulin M,Kulis T,Moore ND,Taylor-Weiner A,Hamid AA,Reardon B,Wubbenhorst B,Godse R,Vaughn DJ,Jacobs LA,Meien S,Grgic M,Kastelan Z,Markt SC,Damrauer SM,Rader DJ,Kember RL,Loud JT,Kanetsky PA,

    更新日期:2019-04-01 00:00:00

  • Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.

    abstract:Importance:RAS wild-type (wt) status is necessary but not sufficient for response to anti-epidermal growth factor receptor (EGFR) agents in advanced colorectal cancer (aCRC). RNA expression of EGFR ligands epiregulin (EREG) and amphiregulin (AREG) may correlate with EGFR-targeted therapy efficacy in aCRC, so may repres...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.6065

    authors: Seligmann JF,Elliott F,Richman SD,Jacobs B,Hemmings G,Brown S,Barrett JH,Tejpar S,Quirke P,Seymour MT

    更新日期:2016-05-01 00:00:00

  • Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.

    abstract:IMPORTANCE:BRCA genetic testing has substantial public health impact, yet little is known of the real-world experiences of the more than 100 000 Americans undergoing testing annually. OBJECTIVE:To identify factors associated with use of BRCA testing, assess whether delivery of genetic counseling and testing services a...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2015.3048

    authors: Armstrong J,Toscano M,Kotchko N,Friedman S,Schwartz MD,Virgo KS,Lynch K,Andrews JE,Aguado Loi CX,Bauer JE,Casares C,Bourquardez Clark E,Kondoff MR,Molina AD,Abdollahian M,Walker G,Sutphen R

    更新日期:2015-12-01 00:00:00

  • Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.

    abstract:IMPORTANCE:Substantial progress has been made in cancer diagnosis and treatment, resulting in a steady improvement in cancer survival. The degree of improvement by age, race, and sex remains unclear. OBJECTIVE:To quantify the degree of survival improvement over time by age, race, and sex in the United States. DESIGN,...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2014.161

    authors: Zeng C,Wen W,Morgans AK,Pao W,Shu XO,Zheng W

    更新日期:2015-04-01 00:00:00

  • Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

    abstract:IMPORTANCE:Hepatocellular carcinoma (HCC) has the second-highest cancer-related mortality rate in the world because most patients are diagnosed at an intermediate to advanced stage when surgery is not suitable. Transcatheter arterial chemoembolization (TACE) is currently considered a first-line therapy for unresectable...

    journal_title:JAMA oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1001/jamaoncol.2015.2189

    authors: Huo YR,Eslick GD

    更新日期:2015-09-01 00:00:00

  • Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.

    abstract:Importance:Epidermal growth factor receptor (EGFR) (HER1) signaling depends on ligand binding and dimerization with itself or other HER receptors. We previously showed in a randomized trial that high EGFR ligand expression is predictive of panitumumab benefit in advanced colorectal cancer. Tumor expression of HER3 may ...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1001/jamaoncol.2017.3168

    authors: Seligmann JF,Hatch AJ,Richman SD,Elliott F,Jacobs B,Brown S,Hurwitz H,Barrett JH,Quirke P,Nixon AB,Seymour MT

    更新日期:2018-04-01 00:00:00

  • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women.

    abstract:Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association w...

    journal_title:JAMA oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1001/jamaoncol.2018.1771

    authors: Premenopausal Breast Cancer Collaborative Group.,Schoemaker MJ,Nichols HB,Wright LB,Brook MN,Jones ME,O'Brien KM,Adami HO,Baglietto L,Bernstein L,Bertrand KA,Boutron-Ruault MC,Braaten T,Chen Y,Connor AE,Dorronsoro M,Dossu

    更新日期:2018-11-01 00:00:00

  • Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer.

    abstract:Importance:Breast cancer risk and comorbidities increase with age. Data are lacking on the association of adjuvant chemotherapy with survival in elderly patients with multiple comorbidities and node-positive breast cancer. Objective:To examine the association of chemotherapy with survival in elderly patients with mult...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2020.2388

    authors: Tamirisa N,Lin H,Shen Y,Shaitelman SF,Sri Karuturi M,Giordano SH,Babiera G,Bedrosian I

    更新日期:2020-10-01 00:00:00

  • Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women.

    abstract:Importance:Colorectal cancer (CRC) incidence and mortality among individuals younger than 50 years (early-onset CRC) are increasing. The reasons for such increases are largely unknown, although the increasing prevalence of obesity may be partially responsible. Objective:To investigate prospectively the association bet...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.4280

    authors: Liu PH,Wu K,Ng K,Zauber AG,Nguyen LH,Song M,He X,Fuchs CS,Ogino S,Willett WC,Chan AT,Giovannucci EL,Cao Y

    更新日期:2019-01-01 00:00:00

  • Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.

    abstract:Importance:Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate end points, including virologic response, and are equally recommended as first-line treatments for patients with chronic hepatitis B (CHB). However, it is unclear whether treatment with these drugs is associated with ...

    journal_title:JAMA oncology

    pub_type: 杂志文章

    doi:10.1001/jamaoncol.2018.4070

    authors: Choi J,Kim HJ,Lee J,Cho S,Ko MJ,Lim YS

    更新日期:2019-01-01 00:00:00